Antibody structure and function: the basis for engineering therapeutics
ML Chiu, DR Goulet, A Teplyakov, GL Gilliland - Antibodies, 2019 - mdpi.com
Antibodies and antibody-derived macromolecules have established themselves as the
mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure …
mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure …
Next generation antibody drugs: pursuit of the'high-hanging fruit'
PJ Carter, GA Lazar - Nature Reviews Drug Discovery, 2018 - nature.com
Antibodies are the most rapidly growing drug class and have a major impact on human
health, particularly in oncology, autoimmunity and chronic inflammatory diseases. Many of …
health, particularly in oncology, autoimmunity and chronic inflammatory diseases. Many of …
Considerations for the design of antibody-based therapeutics
Antibody-based proteins have become an important class of biologic therapeutics, due in
large part to the stability, specificity, and adaptability of the antibody framework. Indeed …
large part to the stability, specificity, and adaptability of the antibody framework. Indeed …
Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans
P Ulrichts, A Guglietta, T Dreier… - The Journal of …, 2018 - Am Soc Clin Investig
BACKGROUND. Intravenous Ig (IVIg), plasma exchange, and immunoadsorption are
frequently used in the management of severe autoimmune diseases mediated by …
frequently used in the management of severe autoimmune diseases mediated by …
Subcutaneous delivery of monoclonal antibodies: how do we get there?
M Viola, J Sequeira, R Seiça, F Veiga, J Serra… - Journal of controlled …, 2018 - Elsevier
The convenience of subcutaneous (SC) administration and the increasing interest in
monoclonal antibody (mAb)-based therapies for chronic diseases, hint their potential for SC …
monoclonal antibody (mAb)-based therapies for chronic diseases, hint their potential for SC …
Antibody-mediated protection against Ebola virus
Recent Ebola virus disease epidemics have highlighted the need for effective vaccines and
therapeutics to prevent future outbreaks. Antibodies are clearly critical for control of this …
therapeutics to prevent future outbreaks. Antibodies are clearly critical for control of this …
An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies
The pH-selective interaction between the immunoglobulin G (IgG) fragment crystallizable
region (Fc region) and the neonatal Fc receptor (FcRn) is critical for prolonging the …
region (Fc region) and the neonatal Fc receptor (FcRn) is critical for prolonging the …
Extending human IgG half-life using structure-guided design
Engineering of antibodies for improved pharmacokinetics through enhanced binding to the
neonatal Fc receptor (FcRn) has been demonstrated in transgenic mice, non-human …
neonatal Fc receptor (FcRn) has been demonstrated in transgenic mice, non-human …
Targeting FcRn to generate antibody-based therapeutics
The MHC class I-related receptor FcRn serves multiple roles ranging from the regulation of
levels of IgG isotype antibodies and albumin throughout the body to the delivery of antigen …
levels of IgG isotype antibodies and albumin throughout the body to the delivery of antigen …
Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics
NM Piche-Nicholas, LB Avery, AC King, M Kavosi… - MAbs, 2018 - Taylor & Francis
ABSTRACT A large body of data exists demonstrating that neonatal Fc receptor (FcRn)
binding of an IgG via its Fc CH2-CH3 interface trends with the pharmacokinetics (PK) of IgG …
binding of an IgG via its Fc CH2-CH3 interface trends with the pharmacokinetics (PK) of IgG …